We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.
- Authors
Kulke, Matthew H; Bergsland, Emily K; Ryan, David P; Enzinger, Peter C; Lynch, Thomas J; Zhu, Andrew X; Meyerhardt, Jeffrey A; Heymach, John V; Fogler, William E; Sidor, Carolyn; Michelini, Ann; Kinsella, Kate; Venook, Alan P; Fuchs, Charles S
- Abstract
Endostatin is a 20-kd proteolytic fragment of collagen XVIII that, in preclinical studies, has been shown to have antiangiogenic and antitumor activity. Both preclinical and human phase I studies of recombinant human endostatin (rhEndostatin) suggested activity in neuroendocrine tumors, which are known to be hypervascular. We therefore performed a multicenter phase II study of rhEndostatin in patients with carcinoid or pancreatic neuroendocrine tumors.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Vol 24, Issue 22, p3555
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2006.05.6762